hVIVO acquires Germany’s CRS for ‘significant European foothold’
Early-stage CRO hVIVO has acquired CRS Clinical Research Services Management GmbH for €10 million in a deal that gives it two trial sites in Germany.
Under the deal the two units, in Mannheim and Kiel, which specialize in cardiometabolic, immunology, and complex PK/PD studies and trials involving renal and hepatic impaired patients, respectively, will be integrated into hVIVO’s network.
According to CRS, the two units – which house 120 beds - generated revenue of €19.9 million last year and €18.6 million in 2023.
CRS’ research facility in Berlin will continue to operate as an independent unit. However, the site will remain as hVIVO’s preferred partner for specialized trials.
hVIVO CEO Yamin “Mo” Khan, said, “The acquisition will establish a significant European footprint for hVIVO, which combined with CRS’ expertise in early clinical development, will create significant synergies and growth opportunities.”
Khan added, “I believe we have significantly strengthened and diversified the business and have enhanced our ability to deliver our target of growing group revenue to £100 million by 2028.”
hVIVO also predicts the deal will create cross-selling opportunities for both itself and sister company Venn Life Sciences, as well as giving it a broader client base and more diverse revenue streams.
In addition, the deal will allow CRS to provide laboratory, biometry, and consulting services, as well as enhancing its CMC, clinical, PK, and regulatory offering.
Outlook
hVIVO restated its outlook for 2025, predicting it will generate revenue of £73 million this year. The UK firm cited the acquisition and recent contracts as revenue drivers.
“Further to recently awarded contracts for hLAB and field studies, the company expects growth to continue in these service lines. Following the acquisition, average contract sizes across the group are anticipated to increase, as well as growth in the CRS sales pipeline,” the company said.
DepositPhotos/j.dudzinski